Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
This Web Collection presents the results of the Sequencing Quality Control 2 (SEQC2) project that sought to evaluate quality-control metrics and human, bacterial and metagenomic reference materials and datasets for next-generation sequencing (NGS) in both regulatory settings and precision medicine. Data from several different laboratories are compared and the performance of different sequencing platforms and data analysis approaches assessed. This is phase IV of a collaboration between government, academic and industry researchers as part of the Microarray Quality Control (MAQC) consortium.
The MicroArray Quality Control consortium—a 16-year international effort led by the FDA and involving hundreds of scientists from academia, industry and government—helped make genomic medicine a reality.
Tumor–normal paired DNA samples from a breast cancer cell line and a matched lymphoblastoid cell line enable calibration of clinical sequencing pipelines and benchmarking ‘tumor-only’ or ‘matched tumor–normal’ analyses.
Li Tai Fang,
Bin Zhu ⋯
The Somatic Mutation Working Group of Sequencing Quality Control Phase II Consortium
A comprehensive comparison of 20 single-cell RNA-seq datasets derived from the two cell lines analyzed using six preprocessing pipelines, eight normalization methods and seven batch-correction algorithms derived from four different sequencing platforms at different centers.